Clinical Trial Update: Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) [Phase 2]

View source ↗

Summary

This document provides a Phase 2 clinical trial update on Anitocabtagene-autoleucel for relapsed or refractory multiple myeloma (iMMagine-1), sponsored by Kite,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anitocabtagene Autoleucel (anitocabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING